FAQ on Soligenix Inc.'s HyBryte™ and Its FDA-Backed Skin Cancer Trial

What is HyBryte™ and what does it treat?

HyBryte™ is a first-in-class photodynamic therapy developed by Soligenix Inc. for the treatment of cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer, achieving a 75% response rate in clinical trials.

Why is the HyBryte™ trial significant?

The trial is significant because it showcases HyBryte’s potential as a non-invasive therapy for CTCL, supported by a U.S. Food and Drug Administration’s Orphan Products Development Grant, indicating strong regulatory backing.

How does HyBryte™ work?

HyBryte™ is a light-activated therapy that uses safe visible light to treat CTCL, offering a novel approach compared to traditional treatments.

Who is involved in the development of HyBryte™?

Soligenix Inc., a late-stage biopharmaceutical company focused on rare diseases, is developing HyBryte™, with the trial supported by FDA funding.

What are the next steps for HyBryte™?

Soligenix plans to continue advancing regulatory discussions for HyBryte™, aiming for potential commercialization following successful Phase 3 study completion.

Where can I find more information about the HyBryte™ trial?

More information can be found on Soligenix’s website at https://www.soligenix.com or by viewing the Benzinga video at https://ibn.fm/zT9L1.

What designations has HyBryte™ received?

HyBryte™ has received Orphan Drug and Fast Track designations from the FDA, highlighting its potential to address an unmet medical need in CTCL treatment.

How does HyBryte™ compare to other treatments for CTCL?

HyBryte™ offers a first-in-class, non-invasive treatment option activated by safe visible light, distinguishing it from more traditional and potentially invasive therapies for CTCL.

What is the significance of the FDA’s Orphan Products Development Grant for HyBryte™?

The FDA’s grant supports the development of HyBryte™, underscoring its potential as a valuable treatment for a rare disease with limited therapeutic options.

Who can I contact for more information about Soligenix and HyBryte™?

For more information, visit Soligenix’s website at https://www.soligenix.com or explore the InvestorWire platform for updates on the company and its developments.